Pharmaceutical Biotechnology
DOI: 10.1007/0-306-47384-4_5
|View full text |Cite
|
Sign up to set email alerts
|

Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 95 publications
0
2
0
Order By: Relevance
“…12-14 ET is a ten-fold more potent vasoconstrictor than angiotensin II and has extremely long-lasting pressor effects. 4 Severe sepsis is characterized by an increase in cardiac output, general vasodilatation and/or hypotension. These cardiovascular changes are mediated by endogenous vasodilatators like nitric oxide and ANP and vasoconstrictors like ET.…”
Section: Discussionmentioning
confidence: 99%
“…12-14 ET is a ten-fold more potent vasoconstrictor than angiotensin II and has extremely long-lasting pressor effects. 4 Severe sepsis is characterized by an increase in cardiac output, general vasodilatation and/or hypotension. These cardiovascular changes are mediated by endogenous vasodilatators like nitric oxide and ANP and vasoconstrictors like ET.…”
Section: Discussionmentioning
confidence: 99%
“…[15][16][17] The developed photoprobe, termed ET A -Cy5.5 (2; Figure 1), is based on PD 156707, a potent ET receptor antagonist with high affinity and ET A selectivity. [18][19][20][21] The tracer was synthesized by reaction of Cy5.5 Nhydroxysuccinimidyl-(NHS-) ester with amino-precursor 1 (see Figure 1). 22 In this study, we examined the biodistribution of the tracer in wild-type CD-1 mice to assess the applicability of the probe to image ET A R expression in vivo.…”
mentioning
confidence: 99%